Histidine

Ustekinumab injection is used to treat plaque psoriasis , ulcerative colitis , Crohn’s disease , and psoriatic arthritis , which are autoimmune disorders. Ustekinumab injection works by targeting specific proteins in the immune system that drive inflammation. By blocking these proteins, ustekinumab helps reduce inflammation, pain, swelling, and skin symptoms. Ustekinumab's mechanism of action (MOA) is an interleukin inhibitor that targets and blocks proteins IL-12 (interleukin-12) and IL-23 (interleukin-23) in the immune system, which improves symptoms in these conditions. Ustekinumab is usually given as an injection under the skin (subcutaneous injection) for most doses except initial doses for Crohn’s disease and ulcerative colitis, which is given as an infusion into a vein (intravenous infusion). Ustekinumab maintenance dose is every 8 to 12 weeks, depending on the condition being treated. Ustekinumab brand name Stelara, was first FDA approved on September 25, 2009. Since then, FDA approval has been received for ustekinumab biosimilars and interchangeable biosimilars.

Ustekinumab injection is used to treat plaque psoriasis , ulcerative colitis , Crohn’s disease , and psoriatic arthritis , which are autoimmune disorders. Ustekinumab injection works by targeting specific proteins in the immune system that drive inflammation. By blocking these proteins, ustekinumab helps reduce inflammation, pain, swelling, and skin symptoms. Ustekinumab's mechanism of action (MOA) is an interleukin inhibitor that targets and blocks proteins IL-12 (interleukin-12) and IL-23 (interleukin-23) in the immune system, which improves symptoms in these conditions. Ustekinumab is usually given as an injection under the skin (subcutaneous injection) for most doses except initial doses for Crohn’s disease and ulcerative colitis, which is given as an infusion into a vein (intravenous infusion). Ustekinumab maintenance dose is every 8 to 12 weeks, depending on the condition being treated. Ustekinumab brand name Stelara, was first FDA approved on September 25, 2009. Since then, FDA approval has been received for ustekinumab biosimilars and interchangeable biosimilars.

You should not use ustekinumab injection or infusion if you: are allergic to the active ingredient ustekinumab or any of the inactive ingredients contained in the medicine. have active tuberculosis; or have received a BCG (Bacillus Calmette and Guérin) vaccine within the past 12 months. Tell your doctor if you have ever had tuberculosis , if anyone in your household has tuberculosis, or if you have recently traveled to an area where tuberculosis is common. To make sure ustekinumab is safe for you, tell your doctor if you have: signs of infection (fever, chills, cough, muscle aches, painful skin sores, diarrhea, pain when you urinate, feeling very tired) chronic infections new or changing skin lesions a latex allergy as the needle cover on the prefilled syringe contains latex phototherapy (light therapy) allergy shots if you recently received or are scheduled to receive any vaccine, people who take this medicine should not receive live vaccines. Tell your doctor if anyone in your house needs a live vaccine. The viruses used in some types of live vaccines can spread to people with a weakened immune system and can cause serious problems. Some people using this medicine have developed skin cancer (non-melanoma). However, these people may have had a higher risk of skin cancer. Talk to your doctor about this risk and what skin symptoms to watch for. You may need to have regular skin exams.

The signs and symptoms that are produced after the acute overdosage of Histidine include Asthmatic reaction, Premature ejaculation, Allergic skin reactions.

People with liver or kidney disease should not supplement amino acids unless under the direction of a health-care professional.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction. If prescribing authority justifies the benefits of the drug against the possible damages, he/she should reevaluate them and consult the reference material and previous studies.

250 to 500 mg (380 (375)) 8 hourly PO —

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Other drugs may interact with ustekinumab, including prescription and over-the-counter medicines, vitamins , and herbal products . Tell your doctor about all your current medicines and any medicine you start or stop using. Not all possible interactions are listed here.

Store in a well closed container, .